
Director/PDMR Shareholding



Description of the Financial instrument, type ordinary shares of €1/15 each of instrument Identification code FR0010397232 **Acquisition of Ordinary Shares** b) Nature of the transaction Price Volume c) Price(s) and volume(s) €9.70 1,541 N/A Single transaction as above Aggregated information: Price Volume d) · Aggregated volume €9,70 1,541 · Price e) Date of the transaction 12 November 2020 f) Place of the transaction Paris Euronext Growth Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them 1. Details of the person discharging managerial responsibilities / person closely associated Jean-Pierre Crinelli - Non-Executive Director a) Name 2. Reason for the Notification See 1(a) - classified as a PDMR of the Company a) Position/status **Initial Notification** b) Initial notification/ Amendment 3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor a) Name Novacyt S.A. b) LEI 213800BWAC2BF295EG28 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted Description of the Financial instrument, type ordinary shares of €1/15 each

of instrument

Identification code FR0010397232 **Acquisition of Ordinary Shares** b) Nature of the transaction Price Volume c) Price(s) and volume(s) €1.274 8,000 N/A Single transaction as above Aggregated information: Price Volume d) · Aggregated volume €1.274 8,000 · Price e) Date of the transaction 20 March 2020 f) Place of the transaction Paris Euronext Growth Contacts Novacyt SA Graham Mullis, Chief Executive Officer Anthony Dyer, Chief Financial Officer +44 (0)1276 600081 SP Angel Corporate Finance LLP (Nominated Adviser and Broker) Matthew Johnson / Charlie Bouverat (Corporate Finance) Vadim Alexandre / Rob Rees (Corporate Broking) +44 (0)20 3470 0470 Numis Securities Limited (Joint Broker) Freddie Barnfield / James Black

+44 (0)20 7260 1000

FTI Consulting (International)

Victoria Foster Mitchell / Mary Whittow

+44 (0)20 3727 1000

victoria.fostermitchell@fticonsulting.com / mary.whittow@fticonsulting.com

FTI Consulting (France)

Arnaud de Cheffontaines

+33 (0)147 03 69 48

arnaud.decheffontaines@fticonsulting.com

About Novacyt Group

The Novacyt Group is an international diagnostics business generating an increasing portfolio of in vitro and molecular diagnostic tests. Its core strengths lie in diagnostics product development, commercialisation, contract design and manufacturing. The Company's lead business units comprise of Primerdesign and Lab21 Products, supplying an extensive range of high-quality assays and reagents worldwide. The Group directly serves microbiology, haematology and serology markets as do its global partners, which include major corporates.

For more information please refer to the website: www.novacyt.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHGPGBAGUPUGMP